Advertisement

Clinical Management of Organophosphorus Nerve Agents’ Poisonings

  • Mohammad Moshiri
  • Anahita Alizadeh
  • Mahdi Balali-Mood
Chapter

Abstract

Organophosphorus nerve agents (NAs) are known as the deadliest chemical warfare agents. The NAs have four classes G, V, and GV agents and Novichok family. They are highly lipophylic. NAs irreversibly inactivate acetylcholine esterase (AChE) and lead to accumulate toxic levels of acetylcholine. Respiratory system is the main organ that is affected by NAs and respiration may be arrested due to central and peripheral dysfunctions. NA exposure is detected through four methods: (I) measurement of AChE activity, (II) evaluation of hydrolysis products in plasma and urine, (III) fluoride reactivation of phosphylated binding sites, and (IV) determination of NAs and metabolites by mass spectrometric methods. The NA treatment should be started as soon as possible by removing victims from the field and administrating atropine and oximes by auto-injectors. Although atropine and different types of oximes are the main antidotes, there are also some adjuvant treatments for NA intoxication including magnesium sulfate, sodium bicarbonate, gacyclidine, benactyzine, tezampanel, hemoperfusion, antioxidants, and bioscavengers. We also review treatments of victims from high-risk groups, such as pregnant women, children, and elderly.

Keywords

Organophosphorus compounds Acetylcholinesterase Chemical warfare agents Nerve agents Oximes Atropine Gacyclidine Benactyzine Magnesium sulfate Sodium bicarbonate Tabun Sarin Soman VX G agents V agents GA GB GF Novichok agent 

References

  1. Adhikari K, Ghosh A, Alauddin MD, Moitra A, Datta AK (2011) Organophosphate poisoning in pregnancy. J Obstet Gynaecol: J Inst Obstet Gynaecol 31(4):290–292. doi:10.3109/01443615.2010.545901Google Scholar
  2. Allon N, Rabinovitz I, Manistersky E, Weissman BA, Grauer E (2005) Acute and long-lasting cardiac changes following a single whole-body exposure to sarin vapor in rats. Toxicol Sci 87(2):385–390PubMedGoogle Scholar
  3. Ainsworth M, Eveleigh JW (1953) Air-way resistance changes in men exposed to GB Vapour (unpublished report). Chemical defense experimental establishment proton down (United Kingdom) London, England. http://oai.dtic.mil/oai/oai?verb=getRecord&metadataPrefix=html&identifier=AD0014839. Accessed 6 Nov 2013
  4. Anonymous (2012a) Material safety data sheet lethal nerve agent sarin (GB). Available at:http://www.gulfweb.org/bigdoc/report/appgb.html. Accessed 13 Aug 2012
  5. Anonymous (2012b) Organophosphate pesticide health monitoring guidelines, PN10466 Version 2Google Scholar
  6. Aracava Y, Pereira EF, Akkerman M, Adler M, Albuquerque EX (2009) Effectiveness of donepezil, rivastigmine, and (±)huperzine A in counteracting the acute toxicity of organophosphorus nerve agents: comparison with galantamine. J Pharmacol Exp Ther 331(3):1014–1024PubMedGoogle Scholar
  7. ATSDR (2012a) Medical management guidelines for nerve agents: Tabun (GA); Sarin (GB); Soman (GD); and VX agency for toxic substances and disease registry. http://www.atsdr.cdc.gov/MHMI/mmg166.pdf
  8. ATSDR (2012b) Nerve agents (GA, GB, GD, VX) Agency for toxic substances and disease registry, division of toxicology. http://www.atsdr.cdc.gov/toxfaqs/tfacts166.pdf
  9. Bajgar J (2004) Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv Clin Chem 38:151–216PubMedGoogle Scholar
  10. Bajgar J, Fusek J, Kassa J, Kuca K, Jun D (2009) Chemical aspects of pharmacological prophylaxis against nerve agent poisoning. Curr Med Chem 16(23):2977–2986PubMedGoogle Scholar
  11. Bajgar J, Kuca K, Fusek J, Jun D, Bartosova L (2010) Cholinesterase reactivators as prophylactics against nerve agents. Curr Bioact Compd 6(1):2–8Google Scholar
  12. Baker MD (2007) Antidotes for nerve agent poisoning: should we differentiate children from adults? Curr Opin Pediatr 19(2):211–215PubMedGoogle Scholar
  13. Balali-Mood M, Balali-Mood K (2005) Nerve agents. In: Brent J (ed) Critical care toxicology. Elsevier Mosby, Philadelphia, pp 1379–1393Google Scholar
  14. Balali-Mood M, Balali-Mood K (2008) Neurotoxic disorders of organophosphorus compounds and their managements. Arch Iran Med 11(1):65–89PubMedGoogle Scholar
  15. Balali-Mood M, Navaeian A (1986) Clinical and paraclinical fndings in 233 patients with sulfur mustard poisoning. In: Heyndrickx B (ed) Proceedings of the second world congress on new compounds in biological and chemical warfare, toxicological evaluation. Ghent University Press, Ghent, pp 464–473Google Scholar
  16. Balali-Mood M, Saber H (2012) Recent advances in the treatment of organophosphorous poisonings. IJMS 37(2):74–91Google Scholar
  17. Balali-Mood M, Shariat M (1998) Treatment of organophosphate poisoning. Experience of nerve agents and acute pesticide poisoning on the effects of oximes. J Physiol Paris 92(5–6):375–378PubMedGoogle Scholar
  18. Balali-Mood M, Ayati MH, Ali-Akbarian H (2005) Effect of high doses of sodium bicarbonate in acute organophosphorous pesticide poisoning. Clin Toxicol (Phila) 43(6):571–574Google Scholar
  19. Balali-Mood M, Balali-Mood K, Hosseini Shirazi F (2006) Recent advances in treatment of acute organophosphorous nerve agents poisoning. IJPR 5(2):79–87Google Scholar
  20. Balali Mood M, Balali Mood B, Moshiri M (2012) Sulfur mustard. In: Wexler P, Greim H, Moser V et al (eds) Encyclopedia of toxicology 3rd Edition. Elsevier (in press)Google Scholar
  21. Barthold CL, Schier JG (2005) Organic phosphorus compounds–nerve agents. Crit Care Clin 21(4):673–689 (v–vi)Google Scholar
  22. Baze WB (1993) Soman-induced morphological changes: an overview in the non-human primate. J Appl Toxicol 13(3):173–177PubMedGoogle Scholar
  23. Benschop HP, De Jong LP (1991) Toxicokinetics of soman: species variation and stereospecificity in elimination pathways. Neurosci Biobehav Rev 15(1):73–77PubMedGoogle Scholar
  24. Black RM, Clarke RJ, Read RW, Reid MT (1994) Application of gas chromatography-mass spectrometry and gas chromatography-tandem mass spectrometry to the analysis of chemical warfare samples, found to contain residues of the nerve agent sarin, sulphur mustard and their degradation products. J Chromatogr A 662(2):301–321PubMedGoogle Scholar
  25. Britt JO Jr, Martin JL, Okerberg CV, Dick EJ Jr (2000) Histopathologic changes in the brain, heart, and skeletal muscle of rhesus macaques, 10 days after exposure to soman (an organophosphorus nerve agent). Comp Med 50(2):133–139PubMedGoogle Scholar
  26. Brown MA, Brix KA (1998) Review of health consequences from high-, intermediate- and low-level exposure to organophosphorus nerve agents. J Appl Toxicol 18(6):393–408PubMedGoogle Scholar
  27. Cheng TC, Calomiris JJ (1996) A cloned bacterial enzyme for nerve agent decontamination. Enzy Microb Technol 18(8):597–601Google Scholar
  28. Clarkson ED, Schulz SM, Railer RF, Smith KH (2012) Median lethal dose determination for percutaneous exposure to soman and VX in guinea pigs and the effectiveness of decontamination with M291 SDK or SANDIA foam. Toxicol Lett 212(3):282–287PubMedGoogle Scholar
  29. Clement JG, Copeman HT (1984) Soman and sarin induce a long-lasting naloxone-reversible analgesia in mice. Life Sci 34(15):1415–1422PubMedGoogle Scholar
  30. Clements JA, Moore JC, Johnson RP, Lynott J (1952) Observations on airway resistance in men given low doses of GB by chamber exposure. Edgewood arsenal, medical Research Laboratory; medical Laboratory Research Report 122Google Scholar
  31. Cole JB, Stellpflug SJ, Gross EA, Smith SW (2011) Wide complex tachycardia in a pediatric diphenhydramine overdose treated with sodium bicarbonate. Pediatr Emerg Care 27(12):1175–1177PubMedGoogle Scholar
  32. Coleman BR, Ratcliffe RH, Oguntayo SA, Shi X, Doctor BP, Gordon RK, Nambiar MP (2008) [+]-Huperzine A treatment protects against N-methyl-D-aspartate-induced seizure/status epilepticus in rats. Chem Biol Interact 175(1–3):387–395PubMedGoogle Scholar
  33. Cowan FM, Shih TM, Lenz DE, Madsen JM, Broomfield CA (1996) Hypothesis for synergistic toxicity of organophosphorus poisoning-induced cholinergic crisis and anaphylactoid reactions. J Appl Toxicol 16:25–33PubMedGoogle Scholar
  34. Darchini-Maragheh E, Nemati-Karimooy H, Hasanabadi H, Balali-Mood M (2012) Delayed neurological complications of sulphur mustard and Tabun poisoning in 43 Iranian Veterans. Basic Clin Pharmacol Toxicol. doi:10.1111/j.1742–7843.2012.00922.x. Epub 2012 Aug 3Google Scholar
  35. Desire B, Saint-Andre S (1986) Interaction of soman with beta-cyclodextrin. Fundam Appl Toxicol 7(4):646–657PubMedGoogle Scholar
  36. Desire B, Saint-Andre S (1987) Inactivation of sarin and soman by cyclodextrins in vitro. Experientia 43(4):395–397PubMedGoogle Scholar
  37. Dhote F, Carpentier P, Barbier L, Peinnequin A, Baille V, Pernot F, Testylier G, Beaup C, Foquin A, Dorandeu F (2012) Combinations of ketamine and atropine are neuroprotective and reduce neuroinflammation after a toxic status epilepticus in mice. Toxicol Appl Pharmacol 259(2):195–209PubMedGoogle Scholar
  38. DM. P (1996) Environment committee armed forces epidemiological board long-term health effects associated with sub-clinical exposures to GB and mustard. Gulf link: Office of the special assistant for Gulf War Illnesses. Available at: www.gul_ink.osd.mil/agent.htmlGoogle Scholar
  39. Doctor BP, Saxena A (2004) In search of an ideal bioscavenger for organophosphate chemical warfare agent toxicity. In: Flora SJS, Romano JA, Baskin SI, Sekhar K (eds) Pharmacological prespectives of toxic chemicals and their antidotes. Narosa, Gwalior, pp 51–67Google Scholar
  40. Dorandeu F, Carpentier P, Baubichon D, Four E, Bernabe D, Burckhart MF, Lallement G (2005) Efficacy of the ketamine-atropine combination in the delayed treatment of soman-induced status epilepticus. Brain Res 1051(1–2):164–175PubMedGoogle Scholar
  41. Drug information online (drug. Com), ATNAA (2012) Available at: http://www.drugs.com/pro/atnaa.html. Accessed 13 Aug 2012
  42. Du D, Wang J, Smith JN, Timchalk C, Lin Y (2009) Biomonitoring of organophosphorus agent exposure by reactivation of cholinesterase enzyme based on carbon nanotube-enhanced flow-injection amperometric detection. Anal Chem 81(22):9314–9320PubMedCentralPubMedGoogle Scholar
  43. Due AH, Trap HC, Langenberg JP, Benschop HP (1994) Toxicokinetics of soman stereoisomers after subcutaneous administration to atropinized guinea pigs. Arch Toxicol 68(1):60–63PubMedGoogle Scholar
  44. Dunn MA, Sidell FR (1998) Progress in medical defense against nerve agents. JAMA 262:649–652Google Scholar
  45. Duysen EG, Li B, Xie W, Schopfer LM, Anderson RS, Broomfield CA, Lockridge O (2001) Evidence for nonacetylcholinesterase targets of organophosphorus nerve agent: supersensitivity of acetylcholinesterase knockout mouse to VX lethality. J Pharmacol Exp Ther 299(2):528–535PubMedGoogle Scholar
  46. Eddleston M, Buckley NA, Checketts H, Senarathna L, Mohamed F, Sheriff MH, Dawson A (2004) Speed of initial atropinisation in significant organophosphorus pesticide poisoning–a systematic comparison of recommended regimens. J Toxicol Clin Toxicol 42(6):865–875PubMedCentralPubMedGoogle Scholar
  47. Eddleston M, Buckley NA, Eyer P, Dawson AH (2008) Management of acute organophosphorus pesticide poisoning. Lancet 371(9612):597–607PubMedCentralPubMedGoogle Scholar
  48. Emerick GL, Peccinini RG, de Oliveira GH (2010) Organophosphorus-induced delayed neuropathy: a simple and efficient therapeutic strategy. Toxicol Lett 192(2):238–244PubMedGoogle Scholar
  49. Engel CC, Jaffer A, Adkins J, Riddle JR, Gibson R (2004) Can we prevent a second ‘Gulf War syndrome’? Population-based healthcare for chronic idiopathic pain and fatigue after war. Adv Psychosom Med 25:102–122PubMedGoogle Scholar
  50. Eyer P (2003) The role of oximes in the management of organophosphorus pesticide poisoning. Toxicol Rev 22(3):165–190PubMedGoogle Scholar
  51. Fest C, Schmidt KJ (1982) The chemistry of organophosphorus pesticides, vol 2, 2nd edn. Springer-Verlag, BerlinGoogle Scholar
  52. Figueiredo TH, Qashu F, Apland JP, Aroniadou-Anderjaska V, Souza AP, Braga MF (2011) The GluK1 (GluR5) Kainate/{alpha}-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist LY293558 reduces soman-induced seizures and neuropathology. J Pharmacol Exp Ther 336(2):303–312PubMedGoogle Scholar
  53. Fuchs-Buder T, Tassonyi E (1996) Magnesium sulphate enhances residual neuromuscular block induced by vecuronium. Br J Anaesth 76(4):565–566PubMedGoogle Scholar
  54. Fullerton CS, Ursano RJ (1990) Behavioral and psychological responses to chemical and biological warfare. Mil Med 155(2):54–59PubMedGoogle Scholar
  55. Fusek J, Bajgar J (1994) Treatment of intoxication with GV compound in laboratory rats. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove 37(2):57–62PubMedGoogle Scholar
  56. Gaydess A, Duysen E, Li Y, Gilman V, Kabanov A, Lockridge O, Bronich T (2010) Visualization of exogenous delivery of nanoformulated butyrylcholinesterase to the central nervous system. Chem Biol Interact 187(1–3):295–298PubMedCentralPubMedGoogle Scholar
  57. Ghanem E, Raushel FM (2005) Detoxification of organophosphate nerve agents by bacterial phosphotriesterase. Toxicol Appl Pharmacol 207(2 Suppl):459–470PubMedGoogle Scholar
  58. Gordon RK, Feaster SR, Russell AJ, LeJeune KE, Maxwell DM, Lenz DE, Ross MC, Doctor BP (1999) Organophosphate skin decontamination using immobilized enzymes. Chem Biol Interact 119–120(0):463–470Google Scholar
  59. Greaves I, Hunt P (2010) Chapter  5: chemical agents. In: Imre R, Mooney TB, Clarke B (eds) Responding to terrorism. Churchill Livingstone, Edinburgh, pp 233–344Google Scholar
  60. Grunwald J, Raveh L, Doctor BP, Ashani Y (1994) Huperzine A as a pretreatment candidate drug against nerve agent toxicity. Life Sci 54(14):991–997PubMedGoogle Scholar
  61. Gunderson CH, Lehmann CR, Sidell FR, Jabbari B (1992) Nerve agents: a review. Neurology 42(5):946–950PubMedGoogle Scholar
  62. Heide EA (2012) Cholinesterase inhibitors: including insecticides and chemical warfare nerve agents Part 5: the intermediate syndrome. 2012 edn. Agency for toxic substances and disease registry (ATSDR), Available at:http://www.atsdr.cdc.gov/csem/csem.asp?csem=11 & po=28
  63. Herz A, Teschemacher H, Hofstetter A, Kurz H (1965) The importance of lipid-solubility for the central action of cholinolytic drugs. Int J Neuropharmacol 4:207–218PubMedGoogle Scholar
  64. Hirbec H, Gaviria M, Vignon J (2001) Gacyclidine: a new neuroprotective agent acting at the N-methyl-D-aspartate receptor. CNS Drug Rev 7(2):172–198PubMedGoogle Scholar
  65. Howland MA (2011) Pyridoxine. In: Nelson L, Lewin N, Howland MA, Hoffman R, Goldfrank L, Flomenbaum NE (eds) Goldfrank’s toxicologic emergencies ninth edition. McGroHill, NewYorkGoogle Scholar
  66. Hurst CG (2008) Decontamination. In: Lenhart MK, Tuorinsky SD (eds) Textbooks of military medicine, medical aspects of chemical warfare. Department of the Army, United States of America, Washington D.C., pp 351–359Google Scholar
  67. Jakubowski M, Heykamp LS, Durst HD, Thomson SA (2001) Preliminary studies in the formation of ethyl methylphosphonofluoridate from rat and human serum exposed to VX and treated with fluoride ion. Anal Lett 4(5):727–747Google Scholar
  68. Jalali N, Balali-Mood M, Jalali I, Shakeri MT (2012) Electrophysiological changes in patients with acute organophosphorous pesticide poisoning. Basic Clin Pharmacol Toxicol 108(4):251–255Google Scholar
  69. Jokanovic M (1989) Role of carboxylesterase in soman, sarin and tabun poisoning in rats. Pharmacol Toxicol 65(3):181–184PubMedGoogle Scholar
  70. Jokanovic M (2001) Biotransformation of organophosphorus compounds. Toxicology 166(3):139–160PubMedGoogle Scholar
  71. Jokanovic M (2009) Current understanding of the mechanisms involved in metabolic detoxification of warfare nerve agents. Toxicol Lett 188(1):1–10PubMedGoogle Scholar
  72. Jokanovic M, Kosanovic M, Maksimovic M (1996) Interaction of organophosphorus compounds with carboxylesterases in the rat. Arch Toxicol 70(7):444–450PubMedGoogle Scholar
  73. Jokanovic M, Kosanovic M, Brkic D, Vukomanovic P (2011) Organophosphate induced delayed polyneuropathy in man: an overview. Clin Neurol Neurosurg 113(1):7–10PubMedGoogle Scholar
  74. Karalliedde L, Wheeler H, Maclehose R, Murray V (2000) Possible immediate and long-term health effects following exposure to chemical warfare agents. Public Health 114(4):238–248PubMedGoogle Scholar
  75. Kassa J (2002) Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents. J Toxicol Clin Toxicol 40(6):803–816PubMedGoogle Scholar
  76. Kassa J (2006) Therapeutic and neuroprotective efficacy of pharmacological pretreatment and antidotal treatment of acute tabun or soman poisoning with the emphasis on pretreatment drug PANPAL. Arh Hig Rada Toksikol 57(4):427–434PubMedGoogle Scholar
  77. Kassa J, Kuca K, Karasova J, Musilek K (2008) The development of new oximes and the evaluation of their reactivating, therapeutic and neuroprotective efficacy against tabun. Mini Rev Med Chem 8(11):1134–1143PubMedGoogle Scholar
  78. Kayouka M, Houzé P, Debray M, Baud FJ (2009a) Acute renal failure enhances the antidotal activity of pralidoxime towards paraoxon-induced respiratory toxicity. Toxicol Lett 189(1):48–56Google Scholar
  79. Kayouka M, Houzé P, Risède P, Debray M, Baud FJ (2009b) Acute renal failure alters the kinetics of pralidoxime in rats. Toxicol Lett 184(1):61–66Google Scholar
  80. Kiss Z, Fazekas T (1979) Arrhythmias in organophosphate poisonings. Acta Cardiol 34(5):323–330PubMedGoogle Scholar
  81. Koller M, Becker C, Thiermann H, Worek F (2010) GC-MS and LC-MS analysis of nerve agents in body fluids: intra-laboratory verification test using spiked plasma and urine samples. J Chromatogr B Analyt Technol Biomed Life Sci 878(17–18):1226–1233PubMedGoogle Scholar
  82. Kovacic P (2003) Mechanism of organophosphates (nerve gases and pesticides) and antidotes: electron transfer and oxidative stress. Curr Med Chem 10(24):2705–2709PubMedGoogle Scholar
  83. Lallement G, Baubichon D, Clarencon D, Galonnier M, Peoc’h M, Carpentier P (1999) Review of the value of gacyclidine (GK-11) as adjuvant medication to conventional treatments of organophosphate poisoning: primate experiments mimicking various scenarios of military or terrorist attack by soman. Neurotoxicol 20(4):675–684Google Scholar
  84. Leikin JB, Thomas RG, Walter FG, Klein R, Meislin HW (2002) A review of nerve agent exposure for the critical care physician. Crit Care Med 30(10):2346–2354PubMedGoogle Scholar
  85. Lepeintre JF, D’Arbigny P, Mathe JF, Vigue B, Loubert G, Delcour J, Kempf C, Tadie M (2004) Neuroprotective effect of gacyclidine. A multicenter double-blind pilot trial in patients with acute traumatic brain injury. Neurochirurgie 50(2–3 Pt 1):83–95Google Scholar
  86. Little PJ, Reynolds ML, Bowman ER, Martin BR (1986) Tissue disposition of [3H]sarin and its metabolites in mice. Toxicol Appl Pharmacol 83(3):412–419PubMedGoogle Scholar
  87. Little PJ, Scimeca JA, Martin BR (1988) Distribution of [3H] diisopropyl fluorophosphate, [3H]soman, [3H]sarin, and their metabolites in mouse brain. Drug Metab Dispos 16(4):515–520PubMedGoogle Scholar
  88. Liu WF (1991) A symptomatological assessment of organophosphate-induced lethality in mice: comparison of atropine and clonidine protection. Toxicol Lett 56(1–2):19–32PubMedGoogle Scholar
  89. Lukey BJ, Hurst CG, Gordon RK, Doctor BP, Clarkson IVE, Slife HF (2004) Six current or potential skin decontaminations for chemical warfare agents exposure–A literature review. In: Flora SJS, Romano JA, Baskin SI, Sekhar K (eds) Pharmacological prespectives of toxic chemicals and their antidotes. Narosa, Gwalior, pp 14–39Google Scholar
  90. Marrs TC, Maynard RL, Sidell FR (1996a) Chemical warfare agents. Toxicology and treatment. Wiley, TorontoGoogle Scholar
  91. Marrs TC, Maynard RL, Sidell FR (1996b) Organophosphate nerve agents. In: Marrs TC, Maynard RL, Sidell FR (eds) Chemical warfare agents: toxicology and treatment. Wiley, New York, pp 83–100Google Scholar
  92. Marrs TC, Rice P, Vale JA (2006) The role of oximes in the treatment of nerve agent poisoning in civilian casualties. Toxicol Rev 25(4):297–323PubMedGoogle Scholar
  93. Marsillach J, Richter RJ, Kim JH, Stevens RC, MacCoss MJ, Tomazela D, Suzuki SM, Schopfer LM, Lockridge O, Furlong CE (2011) Biomarkers of organophosphorus (OP) exposures in humans. Neurotoxicology 32(5):656–660PubMedCentralPubMedGoogle Scholar
  94. Masson P (2011) Evolution of and perspectives on therapeutic approaches to nerve agent poisoning. Toxicol Lett 206(1):5–13PubMedGoogle Scholar
  95. McDonough JH Jr, Shih T-M (1997) Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology. Neurosci Biobehav Rev 21(5):559–579PubMedGoogle Scholar
  96. McDonough JH Jr, McMonagle J, Copeland T, Zoeffel D, Shih TM (1999) Comparative evaluation of benzodiazepines for control of soman-induced seizures. Arch Toxicol 73(8–9):473–478PubMedGoogle Scholar
  97. McDonough JH Jr, Zoeffel LD, McMonagle J, Copeland TL, Smith CD, Shih TM (2000) Anticonvulsant treatment of nerve agent seizures: anticholinergics versus diazepam in soman-intoxicated guinea pigs. Epilepsy Res 38(1):1–14PubMedGoogle Scholar
  98. McLaughlin B, Rickels K, Abidi M, Toro R (1969) Meprobamate-benactyzine (Deprol) and placebo in two depressed outpatient populations. Psychosomatics 10(2):73–81PubMedGoogle Scholar
  99. Mongan PD, Winkley J, Joseph HMI (2006) Nerve and chemical agents. Hospital preparation for bioterror. Academic Press, Burlington, pp 73–88Google Scholar
  100. Monhart V, Fusek J, Brndiar M, Tlustakova M (1994) Use of hemoperfusion in experimental intoxication with nerve agents. Artif Organs 18(10):770–772PubMedGoogle Scholar
  101. Moody RP, Maibach HI (2006) Skin decontamination: importance of the wash-in effect. Food Chemic Toxico 44(11):1783–1788Google Scholar
  102. Moshiri M, Darchini-Maragheh E, Balali-mood M (2012) Advances in toxicology and medical treatment of chemical warfare nerve agents. DARU (J Pharmaceut Sci) 20:80Google Scholar
  103. Munro N (1994) Toxicity of the organophosphate chemical warfare agents GA, GB, and VX: implications for public protection. Environ Health Perspect 102(1):18–38PubMedCentralPubMedGoogle Scholar
  104. Myhrer T, Enger S, Aas P (2008) Anticonvulsant efficacy of drugs with cholinergic and/or glutamatergic antagonism microinfused into area tempestas of rats exposed to soman. Neurochem Res 33(2):348–354PubMedGoogle Scholar
  105. Nakajima T, Sato S, Morita H, Yanagisawa N (1997) Sarin poisoning of a rescue team in the Matsumoto sarin incident in Japan. Occup Environ Med 54(10):697–701PubMedGoogle Scholar
  106. Nakajima T, Sasaki K, Ozawa H, Sekjima Y, Morita H, Fukushima Y, Yanagisawa N (1998) Urinary metabolites of sarin in a patient of the Matsumoto sarin incident. Arch Toxicol 72(9):601–603PubMedGoogle Scholar
  107. Newball HH, Donlon MA, Procell LR, Helgeson EA, Franz DR (1986) Organophosphate-induced histamine release from mast cells. J Pharmacol Exp Ther 238(3):839–845PubMedGoogle Scholar
  108. Newmark J (2004) The birth of nerve agent warfare: lessons from Syed Abbas Foroutan. Neurology 62(9):1590–1596PubMedGoogle Scholar
  109. Newmark J (2005) Nerve agents. Neurol Clin 23(2):623–641PubMedGoogle Scholar
  110. Noort D, Benschop HP, Black RM (2002) Biomonitoring of exposure to chemical warfare agents: a review. Toxicol Appl Pharmacol 184(2):116–126PubMedGoogle Scholar
  111. Nozaki H, Hori S, Shinozawa Y, Fujishima S, Takuma K, Sagoh M, Kimura H, Ohki T, Suzuki M, Aikawa N (1995) Secondary exposure of medical staff to sarin vapor in the emergency room. Intensive Care Med 21(12):1032–1035PubMedGoogle Scholar
  112. Nurulain SN (2012) Different approaches to acute organophosphorus poison treatment. J Pak Med Assoc 62(7):712–717PubMedGoogle Scholar
  113. Oberst FW, Koon WS, Christensen MK, Crook JW, Cresthull P, Freeman G (1968) Retention of inhaled sarin vapor and its effect on red blood cell cholinesterase activity in man. Clin Pharmacol Ther 9(4):421–427PubMedGoogle Scholar
  114. Okayama H, Aikawa T, Okayama M, Sasaki H, Mue S, Takishima T (1987) Bronchodilating effect of intravenous magnesium sulfate in bronchial asthma. JAMA 257(8):1076–1078PubMedGoogle Scholar
  115. Pajoumand A, Shadnia S, Rezaie A, Abdi M, Abdollahi M (2004) Benefits of magnesium sulfate in the management of acute human poisoning by organophosphorus insecticides. Hum Exp Toxicol 23(12):565–569PubMedGoogle Scholar
  116. Pangi B (2002) Consequence management in the 1995 Sarin attacks on the Japanese subway system. Stud Conflict Terrorism 25:421–448Google Scholar
  117. Pazooki S, Solhi H, Vishteh HR, Shadnia S, Beigi MJ (2011) Effectiveness of fresh frozen plasma as supplementary treatment in organophosphate poisoning. Med J Malaysia 66(4):342–345PubMedGoogle Scholar
  118. Pediatric EAdvisoryPParticipants (2004) Atropine use in children after nerve gas exposure. In: Pediatric Expert Advisory Panel(PEAP) Addressing terrorism, Disaiter and public health emergency Columbia university Maliman school of public health, National center for disaster preparedness, New York, pp 1–8Google Scholar
  119. Perera PM, Jayamanna SF, Hettiarachchi R, Abeysinghe C, Karunatilake H, Dawson AH, Buckley NA (2009) A phase II clinical trial to assess the safety of clonidine in acute organophosphorus pesticide poisoning. Trials 10:73. doi:10.1186/1745–6215-10–73PubMedCentralPubMedGoogle Scholar
  120. Perkins MW, Pierre Z, Rezk P, Sabnekar P, Kabra K, Chanda S, Oguntayo S, Sciuto AM, Doctor BP, Nambiar MP (2010) Acute respiratory toxicity following inhalation exposure to soman in guinea pigs. Toxicol Appl Pharmacol 245(2):171–178. doi:10.1016/j.taap.2010.02.016. Epub 2010 Mar 4PubMedGoogle Scholar
  121. Pichamuthu K, Jerobin J, Nair A, John G, Kamalesh J, Thomas K, Jose A, Fleming JJ, Zachariah A, David SS, Daniel D, Peter JV (2010) Bioscavenger therapy for organophosphate poisoning—an open-labeled pilot randomized trial comparing fresh frozen plasma or albumin with saline in acute organophosphate poisoning in humans. Clin Toxicol (Phila) 48(8):813–819Google Scholar
  122. Pohanka M, Karasova JZ, Musilek K, Kuca K, Jung YS, Kassa J (2011) Changes of rat plasma total low molecular weight antioxidant level after tabun exposure and consequent treatment by acetylcholinesterase reactivators. J Enzyme Inhib Med Chem 26(1):93–97PubMedGoogle Scholar
  123. Polhuijs M, Langenberg JP, Benschop HP (1997) New method for retrospective detection of exposure to organophosphorus anticholinesterases: application to alleged sarin victims of Japanese terrorists. Toxicol Appl Pharmacol 146(1):156–161PubMedGoogle Scholar
  124. Rahimi R, Nikfar S, Abdollahi M (2006) Increased morbidity and mortality in acute human organophosphate-poisoned patients treated by oximes: a meta-analysis of clinical trials. Hum Exp Toxicol 25(3):157–162PubMedGoogle Scholar
  125. Rickell DJ, Glenn JF, Houston WE (1987) Medical defense against nerve agents: new direction. Milit Med 152:35–41Google Scholar
  126. Rickett D, Glenn J, Beers ET (1953) Central respiratory effects versus neuromuscular actions of nerve agents. Neurotoxicology 8:466–475Google Scholar
  127. Robinson CP, Choi JJ, Pento JT (1977) Enhancement of intestinal glucose transport following chronic parathion poisoning. J Pharm Sci 66(6):879–880PubMedGoogle Scholar
  128. Ross MC, Broomfield CA, Cerasoli DM, Doctor BP, Lenz DE, Maxwell DM, Saxena A (2008) Chapter 7: nerve agent bioscavenger: development of a new approach to protect against organophosphorus exposure. In: Lenhart MK, Tuorinsky SD (eds) Textbooks of military medicine, medical aspects of chemical warfare. The office of the surgeon general at TMM publications, Washington, pp 243–259Google Scholar
  129. Rubin LS, Goldberg MN (1958) Effect of tertiary and quaternary atropine salts on absolute scotopic threshold changes produced by an anticholinesterase (sarin). J Appl Physiol 12(2):305–310PubMedGoogle Scholar
  130. Schecter WP (2004) Cholinergic symptoms due to nerve agent attack: a strategy for management. Anesthesiol Clin North America 22(3):579–590 (viii)PubMedGoogle Scholar
  131. Seto Y (2009) Decontamination of chemical and biological warfare agents. Yakugaku Zasshi 129(1):53–69PubMedGoogle Scholar
  132. Sidell FR (1974) Soman and sarin: clinical manifestations and treatment of accidental poisoning by organophosphates. Clin Toxicol 7(1):1–17PubMedGoogle Scholar
  133. Sidell FR, Borak J (1992) Chemical warfare agents: II. Nerve agents. Ann Emerg Med 21(7):865–871PubMedGoogle Scholar
  134. Sidell FR, Maynard RL, Marrs TC (2007) Chemical warfare agents: toxicology and treatment. 2nd Revised edn. Wiley-Blackwell (an imprint of John Wiley & Sons Ltd), LondonGoogle Scholar
  135. Sidell FR, Newmark J, McDonough JH (2008) Nerve agents. In: Lenhart MK, Tuorinsky SD (eds) Textbooks of military medicine, medical aspects of chemical warfare. Department of the army, United States of America, pp 155–219Google Scholar
  136. Singer AW, Jaax NK, Graham JS, McLeod CG Jr (1987) Cardiomyopathy in Soman and Sarin intoxicated rats. Toxicol Lett 36(3):243–249PubMedGoogle Scholar
  137. Sivam SP, Hoskins B, Ho IK (1984) An assessment of comparative acute toxicity of diisopropyl-fluorophosphate, tabun, sarin, and soman in relation to cholinergic and GABAergic enzyme activities in rats. Fund Appl Toxicol 4(4):531–538Google Scholar
  138. Smith JS, Fulop ZL, Levinsohn SA, Darrell RS, Stein DG (2000) Effects of the novel NMDA receptor antagonist gacyclidine on recovery from medial frontal cortex contusion injury in rats. Neural Plast 7(1–2):73–91PubMedCentralPubMedGoogle Scholar
  139. Smith WJ, Clark MWG, Talbot TB, Caple PA, Sidell FR, Hurst CG (2008) Chapter 9, Long-term health effects of chemical threat agents In: Lenhart MK, Tuorinsky SD (eds) Textbooks of military medicine, medical aspects of chemical warfare. The office of the surgeon general at TMM publications, Washington, pp 311–338Google Scholar
  140. Subcommittee on Acute Exposure Guideline Levels CoT, National Research Council (2003) Nerve agents GA, GB, GD, GF, and VX. In: Subcommittee on Acute Exposure Guideline Levels, Committee on Toxicology, Council NR (eds) Acute exposure guideline levels for selected airborne chemicals, vol 3. National Academies Press, pp 89–100Google Scholar
  141. Tang SYH, Chan JTS (2002) A review article on nerve agents. Hong Kong J Emerg Med 9:83–89Google Scholar
  142. Tenberken O, Mikler J, Hill I, Weatherby K, Thiermann H, Worek F, Reiter G (2010) Toxicokinetics of tabun enantiomers in anaesthetized swine after intravenous tabun administration. Toxicol Lett 198(2):177–181. doi:10.1016/j.toxlet.2010.06.012PubMedGoogle Scholar
  143. Teran-MacIver M, Larson K (2008) Implication of chemical biological terrorist event for children and pregnant women. MCN 33(4):224–232Google Scholar
  144. Tonkopii V (2003) Oxidative stress in the mechanism of organophosphates neurotoxicity. Toxicol Lett 144(Suppl.1):132Google Scholar
  145. Tryphonas L, Veinot JP, Clement JG (1996) Early histopathologic and ultrastructural changes in the heart of Sprague-Dawley rats following administration of soman. Toxicol Pathol 24(2):190–198PubMedGoogle Scholar
  146. US Army Medical Research Institute of Chemical Defense (1998) Nerve agents. In: (USAMRICD) UAmriocdCccd (ed) Medical management of chemical casualties handbook, 3rd edn. Aberdeen Proving Ground, EdgewoodGoogle Scholar
  147. Valero A, Golan D (1967) Accidental organic phosphorus poisoning: the use of propranolol to counteract vagolytic cardiac effects of atropine. Isr J Med Sci 3(4):582–584PubMedGoogle Scholar
  148. van derSMJ, Lander BJ, van derWH, Langenberg JP, Benschop HP (2003) Toxicokinetics of the nerve agent (±)-VX in anesthetized and atropinized hairless guinea pigs and marmosets after intravenous and percutaneous administration. Toxicol Appl Pharmacol 191(1):48–62Google Scholar
  149. Volans AP (1996) Sarin: guidelines on the management of victims of a nerve gas attack. J Accid Emerg Med 13(3):202–206PubMedCentralPubMedGoogle Scholar
  150. Wang RF, Wang TL (2005) Nerve agents. Disaster Med 4(Suppl 1):S29–S34Google Scholar
  151. Weinbroum AA, Rudick V, Paret G, Kluger Y, Ben Abraham R (2000) Anaesthesia and critical care considerations in nerve agent warfare trauma casualties. Resuscitation 47(2):113–123PubMedGoogle Scholar
  152. Wille T, Tenberken O, Reiter G, Muller S, Le Provost R, Lafont O, Estour F, Thiermann H, Worek F (2009) Detoxification of nerve agents by a substituted beta-cyclodextrin: application of a modified biological assay. Toxicology 265(3):96–100PubMedGoogle Scholar
  153. Wolfe AD, Rush RS, Doctor BP, Koplovitz I, Jones D (1987) Acetylcholinesterase prophylaxis against organophosphate toxicity. Fund Appl Toxicol 9(2):266–270Google Scholar
  154. Worek F, Kleine A, Falke K, Szinicz L (1995) Arrhythmias in organophosphate poisoning: effect of atropine and bispyridinium oximes. Arch Int Pharmacodyn Ther 329(3):418–435PubMedGoogle Scholar
  155. Worek F, Koller M, Thiermann H, Szinicz L (2005) Diagnostic aspects of organophosphate poisoning. Toxicology 214(3):182–189PubMedGoogle Scholar
  156. Worek F, Eyer P, Aurbek N, Szinicz L, Thiermann H (2007) Recent advances in evaluation of oxime efficacy in nerve agent poisoning by in vitro analysis. Toxicol Appl Pharmacol 219(2–3):226–234PubMedGoogle Scholar
  157. Yang CC, Deng JF (2007) Intermediate syndrome following organophosphate insecticide poisoning. J Chin Med Assoc 70(11):467–472PubMedGoogle Scholar
  158. Yergler M (2002) Nerve gas attack. Am J Nurs 102(7):57–60PubMedGoogle Scholar
  159. Yokoyama K, Ogura Y, Kishimoto M, Hinoshita F, Hara S, Yamada A, Mimura N, Seki A, Sakai O (1995) Blood purification for severe sarin poisoning after the Tokyo subway attack. JAMA 274(5):379PubMedGoogle Scholar
  160. Zangara A (2003) The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer’s disease. Pharmacol Biochem Behav 75(3):675–686PubMedGoogle Scholar
  161. Zheng X, Okolotowicz K, Wang B, Macdonald M, Cashman JR, Zhang J (2010) Direct detection of the hydrolysis of nerve agent model compounds using a fluorescent probe. Chem Biol Interact 187(1–3):330–334PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Mohammad Moshiri
    • 1
  • Anahita Alizadeh
    • 2
    • 3
  • Mahdi Balali-Mood
    • 4
  1. 1.Department of Pharmacodynamics and Toxicology, School of PharmacyMashhad University of Medical SciencesMashhadIran
  2. 2.Medical Toxicology Research Center, School of MedicineMashhad University of Medical SciencesMashhadIran
  3. 3.University Department of Clinical Toxicology, Imam Reza Hospital, Faculty of MedicineMashhad University of Medical SciencesMashhadIslamic Republic of Iran
  4. 4.Medical Toxicology Research Centre and University Department of Clinical Toxicology, Imam Reza Hospital, Faculty of MedicineMashhad University of Medical SciencesMashhadIslamic Republic of Iran

Personalised recommendations